Do you want to read an article? Please log in or register.
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Genitourinary Cancer
Related content
COMMENTED
Genitourinary CancerNuclear Medicine
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet Oncol
Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS, UpFrontPSMA Study Team
doi: 10.1016/S1470-2045(24)00440-6
COMMENTED
Nuclear Medicine
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Lancet Oncol
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID, ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
doi: 10.1016/S1470-2045(24)00135-9
Genitourinary Cancer
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer
Prostate Cancer Prostatic Dis
Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D
doi: 10.1038/s41391-024-00930-z
Genitourinary Cancer
Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer
Prostate
Dinckal M, Ergun KE, Kalemci MS, Guler E, Tokac R, Ordu S, Ogut N, Ozgul S, Sanli O, Sen S, Turna B
doi: 10.1002/pros.24799
Genitourinary Cancer
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study
Prostate Cancer Prostatic Dis
Deivasigamani S, Adams ES, Stock S, Kotamarti S, Séguier D, Taha T, Howard LE, Aminsharifi A, Jibara G, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Guerrios-Rivera L, Freedland SJ, Polascik TJ
doi: 10.1038/s41391-024-00880-6
Genitourinary Cancer
Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience
Prostate Cancer Prostatic Dis
Shoji S, Naruse J, Ohno S, Aoki M, Takahashi K, Yuzuriha S, Kuroda S, Umemoto T, Nakajima N, Hasegawa M, Kawamura Y, Kajiwara H, Hashida K, Uemura K, Hasebe T, Tajiri T
doi: 10.1038/s41391-024-00921-0
Gastrointestinal Cancer
Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study
Clin Cancer Res
Slater S, Bryant A, Aresu M, Begum R, Chen HC, Peckitt C, Lazaro-Alcausi R, Carter P, Anandappa G, Khakoo S, Melcher L, Potter V, Marti Marti F, Huang J, Branagan G, George N, Abulafi M, Duff S, Raja A, Gupta A, West N, Bucheit L, Rich T, Chau I, Cunningham D, Starling N
doi: 10.1158/1078-0432.CCR-24-0226
Gynecologic Cancer
Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study
Lancet Oncol
Sundar S, Agarwal R, Davenport C, Scandrett K, Johnson S, Sengupta P, Selvi-Vikram R, Kwong FL, Mallett S, Rick C, Kehoe S, Timmerman D, Bourne T, Van Calster B, Stobart H, Neal RD, Menon U, Gentry-Maharaj A, Sturdy L, Ottridge R, Deeks J, ROCkeTS collaborators
doi: 10.1016/S1470-2045(24)00406-6
Further Publications
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer
Eur J Cancer
Roubaud G, Attard G, Boegemann M, Olmos D, Trevisan M, Antoni L, Pascoe K, Capone C, Van Sanden S, Hashim M, Palmer S, Chi K
doi: 10.1016/j.ejca.2024.114183